ArticleJournal of gastrointestinal oncology2026
Non-surgical management of malignant bowel obstruction: strategies and outcomes in inoperable patients.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Malignant bowel obstruction (MBO) is a complication of advanced abdominal cancer. Management should be individualized, ranging from surgical or endoscopic interventions to symptom control and comfort measures in inoperable cases. This study examines predictors of survival and disparities in treatment among patients with inoperable MBO. Methods: A retrospective cohort study was conducted on 63 patients with MBO treated non-operatively between July 2019 and June 2023 at the University of New Mexico in the Southwestern United States. Of 421 patients screened, exclusions were based on incomplete records or failure to meet clinical and radiological criteria for MBO. Data included demographics, tumor types, treatments, inflammatory markers, and outcomes. Statistical analyses included Results: The cohort included 39 females (61.9%) and 24 males (38.1%) with a mean age of 63.2 years [standard deviation (SD) =13.8]. The most common causes of MBO were gastrointestinal (GI) tumors (46%) and gynecologic cancers (34%). The median survival was 25 days, with significant disparities observed. Non-English speakers had higher odds of survival [odds ratio (OR) =5.56, P=0.04], while sepsis at admission was associated with 100% mortality. Elevated C-reactive protein (CRP) (15.85 Conclusions: Disparities in MBO management highlight gaps in equitable care, particularly gender and language preference. Non-English-speaking patients had a survival advantage, underscoring the importance of culturally tailored care. The underutilization of palliative treatments, such as steroids and octreotide, reveals inconsistencies in guideline adherence. The association of sepsis with 100% mortality reinforces the need for early infection management. Standardized, evidence-based protocols and culturally appropriate care could improve outcomes for this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.